CHS Inc.
NASDAQ:CHSCLAgricultural Farm Products
-$0.05 today
- Market cap
- $294.90M
- Beta
- 0.10
- P/E (TTM)
- 0.0
- EPS (TTM)
- $0.00
- Dividend yield
- 7.37%
Volume 0.12M
Average 0.02M
CHSCL EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
CHS Inc.NASDAQ: CHSCL
EPS (Basic) · Q2 FY2026 · quarter ended Feb 2026
EPS (Basic) remains negative
Q2 FY2026 EPS (Basic) was $0, compared with $0 a year earlier. Trailing-twelve-month EPS (Basic) was $0.
Context
- EPS (Basic) increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly EPS (Basic) holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- 0.00 USD
- Year-over-year change
- —
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-08-31 | 0.00 | — |
| FY2024 | 2024-08-31 | 0.00 | — |
| FY2023 | 2023-08-31 | 0.00 | — |
| FY2022 | 2022-08-31 | 0.00 | — |
| FY2021 | 2021-08-31 | 0.00 | — |
EPS (Basic) vs competitors
How CHSCL compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | ₪6.52 ILS | +26.8% | +25.9% | |
| LTM Mar 2026 | $1.11 USD | +104.5% | — | |
| LTM Mar 2026 | $0.38 USD | +204.1% | — | |
SLSNSolesence, Inc. Common Stock | LTM Mar 2026 | $0.02 USD | -70.1% | — |
| LTM Feb 2026 | $0 USD | — | — | |
| LTM Mar 2026 | -$0.1 USD | -26.0% | — | |
AFRIForafric Global PLC | LTM Jun 2024 | -$0.63 USD | — | — |
| LTM Mar 2026 | -R$0.95 BRL | -117.4% | -35.8% | |
| LTM Apr 2026 | -$0.96 USD | +63.9% | — | |
| LTM Apr 2026 | -$2.28 USD | -329.4% | — | |
| LTM Mar 2026 | -$2.47 USD | +86.6% | — | |
| Peer median (excluding CHSCL) | — | +26.8% | -5.0% | |
Competitors are the stored peer set for CHSCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Aug 2021 | FY2022 Aug 2022 | FY2023 Aug 2023 | FY2024 Aug 2024 | FY2025 Aug 2025 |
|---|---|---|---|---|---|
| Revenue | 38.45B | 47.79B | 45.59B | 39.26B | 35.46B |
| Cost of Revenue | 36.57B | 45.1B | 42.81B | 37.51B | 34.33B |
| Gross Profit | 1.88B | 2.69B | 2.78B | 1.75B | 1.14B |
| Gross Margin | 4.9% | 5.6% | 6.1% | 4.5% | 3.2% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 746.71M | 998.41M | 1.03B | 1.15B | 1.05B |
| Operating Expenses | 746.71M | 998.41M | 1.03B | 1.17B | 1.05B |
| Depreciation & Amortization | 461.73M | 461.97M | 464.62M | 481.72M | 651.43M |
| EBITDA | 1.08B | 2.39B | 2.61B | 1.68B | 1.41B |
| EBITDA Margin | 2.8% | 5.0% | 5.7% | 4.3% | 4.0% |
| Operating Income | 1.13B | 1.69B | 1.75B | 584.36M | 90.76M |
| Operating Margin | 2.9% | 3.5% | 3.8% | 1.5% | 0.3% |
| Interest Income | 104.57M | 114.16M | 0 | 0 | 0 |
| Interest Expense | 112.57M | 120.26M | 137.44M | 104.06M | 146.08M |
| Other Income / Expenses | (614.41M) | 115.96M | 257.06M | 513.43M | 524.02M |
| Income Before Tax | 515.32M | 1.81B | 2.01B | 1.1B | 614.77M |
| Pre-Tax Margin | 1.3% | 3.8% | 4.4% | 2.8% | 1.7% |
| Income Tax Expense | (38.25M) | 132.12M | 107.66M | (4.87M) | 16.78M |
| Net Income | 553.95M | 1.68B | 1.9B | 1.1B | 597.92M |
| Net Margin | 1.4% | 3.5% | 4.2% | 2.8% | 1.7% |
| EPS (Basic) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS (Diluted) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares | 0 | 0 | 0 | 0 | 0 |
| Weighted Avg Shares (Diluted) | 0 | 0 | 0 | 0 | 0 |
CHS Inc.
NASDAQ:CHSCL
Intrinsic Alpha fair value
Locked
Current Price
$24.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.